IN8bio
INAB
21 hedge funds and large institutions have $5.35M invested in IN8bio in 2026 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 1 closing their positions.
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
67% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 3
11% more funds holding
Funds holding: 19 → 21 (+2)
0.38% more ownership
Funds ownership: 38.11% → 38.49% (+0.38%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
4% less capital invested
Capital invested by funds: $5.55M → $5.35M (-$209K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$95K |
| 2 |
OC
Oppenheimer & Co
New York
|
+$58.8K |
| 3 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$48K |
| 4 |
Renaissance Technologies
New York
|
+$18.2K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$3.73K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
BIOS Capital Management
Fort Worth,
Texas
|
-$131K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
-$20.6K |
| 3 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$18.4K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$722 |
INAB Hedge Fund Activity: Q2 2026 in Review
21 of the 8,320 institutional investors tracked by Wall St. Rank reported a position in IN8bio (INAB) for Q2 2026, worth a combined $5.35M — down 3.8% from $5.55M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new INAB positions and 1 closed out — a net gain of 2 holders — while 5 added to existing stakes and 3 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $95K. The largest seller was BIOS Capital Management, cutting an estimated $131K.
- 21 institutional investors held IN8bio (INAB) as of Q2 2026, up from 19 in Q1 2026.
- Funds reported $5.35M of IN8bio stock for Q2 2026, down 3.8% quarter-over-quarter.
- 3 funds opened new IN8bio positions in Q2 2026 and 1 closed out, a net change of +2 holders.
- The largest IN8bio buyer in Q2 2026 was Citadel Advisors, an estimated $95K added.
- The largest IN8bio seller in Q2 2026 was BIOS Capital Management, an estimated $131K sold.
Based on aggregated 13F filings for Q2 2026.